secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K/A
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001493152-23-024106
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage reduces CEO milestone stock options from 488,256 to 267,616 shares
---------------------------------------------------------------------------

- Amendment corrects Milestone Grant for CEO Junli He from 488,256 to 267,616 shares.
- Each vesting increment reduced from 244,128 to 133,808 shares, still two tranches.
- Effective retroactively to March 14, 2023; no other changes to employment agreement.
- Reduction lowers potential dilution from milestone options by approximately 45%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223024106/0001493152-23-024106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223024106/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-024106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer